Vnitr Lek 2023, 69(7):E10-E14 | DOI: 10.36290/vnl.2023.093

Cancer after kidney transplantation

Anna Novotná, Silvie Rajnochová­ Bloudíčková
Klinika nefrologie, Institut klinické a experimentální medicíny, Praha

Cancer is the second cause of death in kidney transplant recipients. The incidence increases with the post-transplant period. The etiology is multifactorial; in addition to traditional risk factors, the effects of immunosuppressive treatment and impaired immunosurveillance play a decisive role. Posttransplant cancer can occur as a result of transmission from the donor, de novo or as a relapse. Both transplant candidates and donors must be carefully examined to rule out an active cancer. Eligibility of recipients and donors with a history of cancer depends on the cancer type, stage and current restaging. Along with conventional therapeutic approaches, the post-transplant cancer treatment also includes a modification of immunosuppressive treatment. Post-transplant care includes oncology screening based on the general KDIGO (Kidney Disease: Improving Global Outcomes) from 2009 and national oncological recommendations from 2023.

Keywords: immunosuppression, kidney, cancer, screening, transplantation.

Accepted: October 26, 2023; Published: October 26, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotná A, Bloudíčková SR. Cancer after kidney transplantation. Vnitr Lek. 2023;69(7):E10-14. doi: 10.36290/vnl.2023.093.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost­‑utility of renal transplantation. Kidney Int. 1996 Jul;50(1):235-42. Go to original source... Go to PubMed...
    2. Domácí i zahraniční statistiky. Koordinační středisko transplantací. [cit. 2023-05-10]. Available from: https://kst.cz/statistiky/.
    3. Estimated number of worldwide kidney transplants in 2021, by region. Data from 2021. Statita. [cit. 2023-05-10]. Available from: https://www.statista.com/statistics/398657/kidney­‑transplants­‑by­‑world­‑region/.
    4. Au E, Wong G, Chapman JR. Cancer in kidney transplant recipients. Nat Rev Nephrol. 2018 Aug;14(8):508-520. Go to original source... Go to PubMed...
    5. van de Wetering J, Roodnat JI, Hemke AC, et al. Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case­‑control study. Transplantation. 2010 Dec 27;90(12):1542-6. Go to original source... Go to PubMed...
    6. Clinical practice guideline for the care of kidney transplant recipients. Data from 2009. KDIGO. [cit. 2023-05-10]. Available from: https://kdigo.org/wp­‑content/uploads/2022/09/KDIGO-2009-Transplant­‑Recipient­‑Guideline­‑English.pdf.
    7. ANZDATA 39th Annual Report 2016 (Data to 2015). Data from 2016. ANZDATA. [cit. 2023-05-10]. Available from: https://www.anzdata.org.au/wp­‑content/uploads/2018/04/c10_cancer_v2.0_20170418.pdf.
    8. Yanik EL, Clarke CA, Snyder JJ, et al. Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. J Am Soc Nephrol. 2016 May;27(5):1495-504. Go to original source... Go to PubMed...
    9. Celková zátěž zhoubnými novotvary v ČR. Data from February 2021. Ústav zdravotnických informací a statistiky. [cit. 2023-05-10]. Available from: https://www.uzis.cz/index.php?pg=aktuality & aid=8466.
    10. Desai R, Collett D, Watson CJ, et al. Cancer transmission from organ donors­‑unavoidable but low risk. Transplantation. 2012 Dec 27;94(12):1200-7. Go to original source... Go to PubMed...
    11. Xiao, D. et al. Donor cancer transmission in kidney transplantation: a systematic review. Am. J. Transplant. 2013, 2645-2652. Go to original source... Go to PubMed...
    12. Webster AC, Craig JC, Simpson JM, et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant. 2007 Sep;7(9):2140-51. Go to original source... Go to PubMed...
    13. Wong G, Turner RM, Chapman JR, et al.Time on dialysis and cancer risk after kidney transplantation. Transplantation. 2013 Jan 15;95(1):114-21. Go to original source... Go to PubMed...
    14. Vajdic, C. M. et al. Cancer incidence before and after kidney transplantation. JAMA 296;2823-2831(2006). Go to original source... Go to PubMed...
    15. European Renal Best Practice Transplantation Guideline Development Group. ERBP Guideline on the Management and Evaluation of the Kidney Donor and Recipient. Nephrol Dial Transplant. 2013 Aug;28 Suppl 2:ii1-71. Go to original source... Go to PubMed...
    16. Morteau O, et al. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo. PLoS ONE 5, e13294 (2010). Go to original source... Go to PubMed...
    17. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta­‑analysis. Lancet 2007;370:59-67. Go to original source... Go to PubMed...
    18. Kuschal C, Thoms KM, Boeckmann L, et al. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition. Exp Dermatol. 2011;20:795-799. Go to original source... Go to PubMed...
    19. Badve SV, Pascoe EM, Burke M, et al. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1845-1855. Go to original source... Go to PubMed...
    20. Desai R, Collett D, Watson CJ, et al. Cancer transmission from organ donors­‑unavoidable but low risk. Transplantation. 2012 Dec 27;94(12):1200-7. Go to original source... Go to PubMed...
    21. Chin­‑Hong PV, Kwak EJ. AST Infectious Diseases Community of Practice. Human papillomavirus in solid organ transplantation. Am J Transplant. 2013 Mar;13:189-200. Go to original source... Go to PubMed...
    22. Nalesnik MA, et al. Donor- transmitted malignancies in organ transplantation: assessment of clinical risk. Am. J. Transplant. 2011;1140-1147. Go to original source... Go to PubMed...
    23. Clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Data from 2020. KDIGO. [cit. 2023-05-10]. Available from: https://kdigo.org/wp­‑content/uploads/2018/08/KDIGO­‑Txp­‑Candidate­‑GL­‑FINAL.pdf.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.